Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.16
(-3.53%)
SEK 0.16
(-3.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 238.72 Million SEK | 314.33% |
| 2022 | 57.61 Million SEK | 399.59% |
| 2021 | 11.53 Million SEK | 69.08% |
| 2020 | 6.82 Million SEK | 1036.83% |
| 2019 | 600 Thousand SEK | -99.47% |
| 2018 | 112.95 Million SEK | 443.8% |
| 2017 | 20.77 Million SEK | 734.14% |
| 2016 | 2.49 Million SEK | 474.46% |
| 2015 | 433.46 Thousand SEK | 128.59% |
| 2014 | 189.62 Thousand SEK | 0.05% |
| 2013 | 189.52 Thousand SEK | -80.88% |
| 2012 | 991.08 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 14.06 Million SEK | -78.97% |
| 2024 Q2 | 52 Million SEK | 269.61% |
| 2024 Q3 | 66.81 Million SEK | 28.48% |
| 2023 Q3 | 58.89 Million SEK | 15.24% |
| 2023 Q4 | 66.89 Million SEK | 13.59% |
| 2023 Q2 | 51.1 Million SEK | -17.31% |
| 2023 FY | 238.72 Million SEK | 314.33% |
| 2023 Q1 | 61.8 Million SEK | 196.23% |
| 2022 Q2 | 15.63 Million SEK | 117.4% |
| 2022 Q4 | 20.86 Million SEK | 49.71% |
| 2022 FY | 57.61 Million SEK | 399.59% |
| 2022 Q1 | 7.19 Million SEK | -37.66% |
| 2022 Q3 | 13.93 Million SEK | -10.85% |
| 2021 Q2 | 2.48 Million SEK | -2.32% |
| 2021 Q1 | 2.54 Million SEK | -62.69% |
| 2021 FY | 11.53 Million SEK | 69.08% |
| 2021 Q4 | 11.53 Million SEK | 400.78% |
| 2021 Q3 | 2.3 Million SEK | -7.36% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 6.82 Million SEK | 1036.83% |
| 2020 Q4 | 6.82 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | 600 Thousand SEK | 0.0% |
| 2019 FY | 600 Thousand SEK | -99.47% |
| 2019 Q1 | - SEK | -100.0% |
| 2018 Q3 | 2.44 Million SEK | -46.14% |
| 2018 Q2 | 4.53 Million SEK | -47.4% |
| 2018 Q4 | 97.36 Million SEK | 3888.69% |
| 2018 Q1 | 8.61 Million SEK | -9.64% |
| 2018 FY | 112.95 Million SEK | 443.8% |
| 2017 Q4 | 9.53 Million SEK | 20214.2% |
| 2017 Q3 | -47.4 Thousand SEK | -101.05% |
| 2017 Q2 | 4.51 Million SEK | -34.0% |
| 2017 FY | 20.77 Million SEK | 734.14% |
| 2017 Q1 | 6.83 Million SEK | 1184.42% |
| 2016 Q2 | 1.03 Million SEK | 20.88% |
| 2016 Q3 | 71.84 Thousand SEK | -93.04% |
| 2016 Q1 | 853.75 Thousand SEK | 586.6% |
| 2016 Q4 | 532.5 Thousand SEK | 641.23% |
| 2016 FY | 2.49 Million SEK | 474.46% |
| 2015 Q2 | 75 Thousand SEK | -27.98% |
| 2015 Q1 | 104.13 Thousand SEK | 384.35% |
| 2015 FY | 433.46 Thousand SEK | 128.59% |
| 2015 Q4 | 124.34 Thousand SEK | -4.34% |
| 2015 Q3 | 129.98 Thousand SEK | 73.32% |
| 2014 Q3 | 22.29 Thousand SEK | 0.0% |
| 2014 Q4 | 21.5 Thousand SEK | -3.55% |
| 2014 FY | 189.62 Thousand SEK | 0.05% |
| 2013 FY | 189.52 Thousand SEK | -80.88% |
| 2012 FY | 991.08 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -310.844% |
| Ziccum AB (publ) | 3.74 Million SEK | -6271.204% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 61.245% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -372.871% |
| Mendus AB (publ) | 28.48 Million SEK | -738.028% |
| Genovis AB (publ.) | 158.23 Million SEK | -50.873% |
| Intervacc AB (publ) | 8.01 Million SEK | -2878.528% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -5357.91% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | -40.066% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -443.851% |
| Aptahem AB (publ) | 2.63 Million SEK | -8974.912% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -22965.604% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -309937.662% |
| Fluicell AB (publ) | 3.33 Million SEK | -7051.857% |
| Saniona AB (publ) | 16.84 Million SEK | -1317.631% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -1355.044% |
| Biovica International AB (publ) | 7.29 Million SEK | -3174.746% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -19744.472% |
| AcouSort AB (publ) | 10.55 Million SEK | -2162.62% |
| Xintela AB (publ) | 78 Thousand SEK | -305962.821% |
| Abliva AB (publ) | 137 Thousand SEK | -174154.745% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -314.46% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -11753.476% |
| OncoZenge AB (publ) | 3000.00 SEK | -7957533.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -153918.71% |
| CombiGene AB (publ) | 5.54 Million SEK | -4205.988% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 80.219% |
| Camurus AB (publ) | 1.71 Billion SEK | 86.095% |
| Corline Biomedical AB | 25.03 Million SEK | -853.771% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -4104.456% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -33010.818% |
| I-Tech AB | 120.86 Million SEK | -97.524% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | -78.031% |
| Cyxone AB (publ) | 5.14 Million SEK | -4537.315% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -3286.227% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -2138.497% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -2025.803% |
| Nanologica AB (publ) | 1.44 Million SEK | -16443.936% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -450332.075% |
| BioInvent International AB (publ) | 71.46 Million SEK | -234.069% |
| Alzinova AB (publ) | 270 Thousand SEK | -88318.148% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -577.822% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -16217.549% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -8359.568% |
| Simris Alg AB (publ) | 4.35 Million SEK | -5382.981% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -183537.692% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -1037852.174% |